中枢神経系治療薬市場：疾患別、薬物クラス別-2023-2030年の世界予測

中枢神経系治療薬の世界市場は、2023年にCAGR 9.30%で701億7,000万米ドル、2030年には1,313億9,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の中枢神経系治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.中枢神経系治療薬の世界市場規模および予測は？

2.予測期間中、世界の中枢神経系治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.中枢神経系治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.中枢神経系治療薬の世界市場における競争戦略は？

5.中枢神経系治療薬の世界市場における技術動向と規制の枠組みは？

6.中枢神経系治療薬の世界市場における主要ベンダーの市場シェアは？

7.中枢神経系治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • CNS疾患の有病率の上昇と効果的な治療選択肢への需要の増加
    • 主要製品の特許満了により後発品の承認が増加
    • 新興市場におけるヘルスケアインフラの改善
  • 抑制要因
    • 新しい治療薬の価格上昇に伴う懸念
  • 機会
    • CNS疾患の診断と治療の進歩
    • 製薬会社によるたゆまぬ研究開発の取り組み
  • 課題
    • 厳格かつ延長された医薬品承認手続き
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 中枢神経系治療薬市場病気別

• がん
• 変性疾患
  • アルツハイマー病
  • 筋萎縮性側索硬化症
  • 多発性硬化症
  • パーキンソン病
• 感染症
• メンタルヘルス
  • 不安障害
  • てんかん
  • 精神障害
• 神経血管疾患
• トラウマ

第7章 中枢神経系治療薬市場薬物クラス別

• 鎮痛剤
• 麻酔薬
• 抗てんかん薬
• 抗パーキンソン病薬
• 抗うつ薬
• 中枢神経系興奮剤

第8章 南北アメリカの中枢神経系治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の中枢神経系治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの中枢神経系治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2022 VS 2030 (%)
• FIGURE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
• FIGURE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 14. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 42. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 65. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 68. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 69. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 137. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 138. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 153. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 154. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 157. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 158. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 195. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 196. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 197. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET LICENSE & PRICING

The Global Central Nervous System Therapeutics Market is forecasted to grow significantly, with a projected USD 70.17 billion in 2023 at a CAGR of 9.30% and expected to reach a staggering USD 131.39 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Diseases, market is studied across Cancer, Degenerative Diseases, Infectious Diseases, Mental Health, Neurovascular Diseases, and Trauma. The Degenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Mental Health is further studied across Anxiety Disorders, Epilepsy, and Psychotic Disorders. The Infectious Diseases is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, Antidepressant, and CNS stimulants. The Antidepressant is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Therapeutics Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Central Nervous System Therapeutics Market, by Diseases, 2022 vs 2030
• 4.3. Central Nervous System Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.4. Central Nervous System Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of CNS disorders and increasing demand for effective therapeutic options
    • 5.1.1.2. Increasing approval of generic products due to patent expiration of key products
    • 5.1.1.3. Improving healthcare infrastructure in emerging markets
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with increasing prices of new treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in diagnostics and therapeutics of CNS diseases
    • 5.1.3.2. Constant R&D efforts by pharmaceutical companies
  • 5.1.4. Challenges
    • 5.1.4.1. Strict & extended drug approval procedures
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Central Nervous System Therapeutics Market, by Diseases

• 6.1. Introduction
• 6.2. Cancer
• 6.3. Degenerative Diseases
  • 6.3.1. Alzheimer's Disease
  • 6.3.2. Amyotrophic Lateral Sclerosis
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Parkinson's Disease
• 6.4. Infectious Diseases
• 6.5. Mental Health
  • 6.5.1. Anxiety Disorders
  • 6.5.2. Epilepsy
  • 6.5.3. Psychotic Disorders
• 6.6. Neurovascular Diseases
• 6.7. Trauma

7. Central Nervous System Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Analgesics
• 7.3. Anesthetics
• 7.4. Anti-Epileptics
• 7.5. Anti-Parkinson Drugs
• 7.6. Antidepressant
• 7.7. CNS stimulants

8. Americas Central Nervous System Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Central Nervous System Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Central Nervous System Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing